The Supreme Court has ordered an interim stay on the National Company Law Appellate Tribunal’s (NCLAT’s) ruling on the resolution of debt-ridden Orchid Pharma.
The NCLAT in November set aside the National Company Law Tribunal’s (NCLT’s) approval of a resolution plan by Gurgaon-based Dhanuka Laboratories for Orchid and remitted the matter to the NCLT, observing that it quoted an amount below the liquidation value and could not be approved.
State Bank of India, which is an important member in the Committee of Creditors (CoC), filed the appeal with the Supreme Court to set aside the NCLAT order, alleging that the appellate tribunal erred in overriding the commercial wisdom of the CoC.
A majority of the committee members had approved Dhanuka’s plan. The NCLAT passed the order based on an appeal by Accord Life Spec, part of the Rs 1,700-crore Accord Group, established by Dravida Munnetra Kazhagam leader and former Union minister of state S Jagathrakshakan, whose resolution plan was rejected by the NCLT, Chennai, while approving Dhanuka’s plan.
Confirming that the Supreme Court has issued an interim stay on the NCLAT order, Vipin Warrier, partner of law firm India Law LLP, who has been advising and representing the resolution professional, said a possibility that could have followed the NCLAT order was the liquidation of Orchid Pharma, which would have affected all the stakeholders, including around 1,400 employees of the company. He said the apex court had issued notice to the respondents — Accord Life Spec, Orchid Pharma, and Dhanuka Laboratories — and it was returnable in four weeks.
Orchid Pharma owes banks more than Rs 3,000 crore. Earlier, the NCLT nullified a resolution plan by US-based Ingen Capital after it was approved since the investor allegedly did not bring in money in accordance with the norms.
Accord, in its appeal at the NCLAT, alleged that Dhanuka’s actual resolution value proposed was Rs 570 crore as against liquidation value of Rs 1,309 crore. It requested the appellate tribunal to set aside the NCLT decision approving Dhanuka’s plan. It has also filed another appeal against the NCLT’s decision to reject Accord’s plan.
The NCLAT dismissed the second appeal. The resolution plan submitted by Accord was also less than the liquidation value.
The NCLT, in its order in June, this year, said while Dhanuka’s resolution plan value was Rs 570 crore, which is lower than the liquidation value of Rs 1,309 crore (according to the resolution professional’s explanation), Orchid Pharma had a cash and bank balance of Rs 321.98 crore. This and some factors brought the plan value to around Rs 1,116.04 crore, close to the liquidation value.
Source: Business-Standard